Hepatitis C virus: Strategies to evade antiviral responses

Future Virology

Volumn 9, Issue 12, 2014, Pages 1061-1075

  Gokhale, Nandan S ^a   Vazquez, Christine ^a   Horner, Stacy M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HCV; IFN; immune evasion; ISGs; MAVS; NS3 4A; RIG I

Indexed keywords

HEPATITIS C VIRUS 4A PROTEASE; HEPATITIS C VIRUS NS3; INTERFERON; INTERFERON DELTA; PATTERN RECOGNITION RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG; VIRUS ENZYME;

CHRONIC LIVER DISEASE; GENE; GENE LOCUS; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; INTERFERON STIMULATED GENE; LIVER; NONHUMAN; OUTCOME ASSESSMENT; PERSISTENT INFECTION; REVIEW; VIRUS ACTIVATION; VIRUS IMMUNITY;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 84919783001     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.14.89     Document Type: Review

References (141)

1. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin. Infect. Dis. 55(Suppl. 1), S10-S15 (2012).
2. Lavanchy D The global burden of hepatitis C Liver Int. 29(Suppl. 1 74-81 2009).
3. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56 S88-S100 (2012).
4. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J. Hepatol. 58(3), 583-592 (2013).
5. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 349, g3308 (2014).
6. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J. Virol. 83(15), 7366-7374 (2009).
7. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5(6), 453-463 (2007).
8. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat. Med. 19(7), 859-868 (2013).
9. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265), 798-801 (2009).
10. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
11. Horner SM, Gale Jr. M. Regulation of hepatic innate immunity by hepatitis C virus. Nat. Med. 19(7), 879-888 (2013).
12. Sumpter R Jr., Loo YM, Foy E et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79( 5), 2689-2699 (2005).
13. Israelow B, Narbus CM, Sourisseau M, Evans MJ. HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hep atology 60( 4 ), 1170-1179 (2014).
14. Goubau D, Deddouche S, Reis ESC. Cytosolic Sensing of Viruses. Immunity 38(5), 855-869 (2013).
15. Baum A, Sachidanandam R, Garcia-Sastre A. Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc. Natl Acad. Sci. USA 107(37), 16303-16308 (2010).
16. Schnell G, Loo YM, Marcotrigiano J, Gale Jr. M. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. PLoS Pathog. 8(8), e1002839 (2012).
17. Saito T, G ale M, Jr. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J. Exp. Med. 205(7), 1523-1527 (2008).
18. Uzri D, Gehrke L. Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J. Virol. 83(9), 4174-4184 (2009).
19. Goubau D, Schlee M, Deddouche S et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5-diphosphates. Nature 514 (7522 ), 372-375 (2014).
20. Luo D, Ding SC, Vela A, Kohlway A, Lindenbach BD, Pyle AM. Structural insights into RNA recognition by RIG-I. Cell 147(2), 409-422 (2011).
21. Jiang F, Ramanathan A, Miller MT et al. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature 479(7373), 423-427 (2011).
22. Kowalinski E, Lunardi T, Mccarthy AA et al. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 147(2), 423-435 (2011).
23. Wu B,Peisley A,Richards C,et al Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5 Cell 152 1-2 276-289 (2013).
24. Peisley A, Wu B, Yao H, Walz T, Hur S. RIG-I forms signaling-competent filaments in an ATP-dependent, ubiquitin-independent manner. Mol. Cell 51(5), 573-583 (2013).
25. Peisley A, Wu B, Xu H, Chen ZJ, Hur S. Structural basis for ubiquitin-mediated antiviral signal activation by RIG-I. Nature 509(7498), 110-114 (2014).
26. Saito T, Hirai R, Loo YM et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc. Natl Acad. Sci. USA 104(2), 582-587 (2007).
27. Oshiumi H, Miyashita M, Matsumo to M, Seya T. A distinct role of Riplet-mediated K63-Linked polyubiquitination of the RIG-I repressor domain in human antiviral innate immune responses. PLoS Pathog. 9(8), e1003533 (2013).
28. Gack MU, Shin YC, Joo CH et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446(7138), 916-920 (2007).
29. Wies E, Wang MK, Maharaj NP et al. Dephosphorylation of the RNA Sensors RIG-I and MDA5 by the Phosphatase PP1 is essential for innate immune signaling. Immunity 38(3), 437-449 (2013).
30. Kato H, Takeuchi O, Mikamo-Satoh E et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205(7), 1601-1610 (2008).
31. Pich lmair A, Schulz O, Tan CP et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J. Virol. 83(20), 10761-10769 (2009).
32. Triantafilou K, Vakaki s E, Kar S, Richer E, Evans GL, Triantafilou M. Visualisation of direct interaction of MDA5 and the dsRNA replicative intermediate form of positive strand RNA viruses. J. Cell Sci. 125(Pt 20), 4761-4769 (2012).
33. Peisley A, Lin C, Wu B et al. Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. Proc. Natl Acad. Sci. USA 108(52), 21010-21015 (2011).
34. Schoggins JW, Wilson SJ, Panis M et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472(7344), 481-485 (2011).
35. Andrus L, Marukian S, Jones CT et al. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology 54(6), 1901-1912 (2011).
36. Hoffmann F, Schmidt A, Dittmann Chevillotte M et al. Polymorphisms in MDA-5 link protein function to clearance of hepatitis C virus. Hepatology doi:10.1002/hep.27344 (2014) (Epub ahead of print).
37. Errett JS, Suthar MS, Mcmillan A, Diamond MS, Gale Jr. M. The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection. J. Virol. 87(21), 11416-11425 (2013).
38. Dixit E, Boulant S, Zhang Y et al. Peroxisomes are signaling platforms for antiviral innate immunity. Cell 141(4), 668-681 (2010).
39. Horner SM, Liu HM, Park HS, Briley J, Gale Jr. M. Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. Proc. Natl Acad. Sci. USA 108(135) 14590-14595 (2011).
40. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122(5), 669-682 ( 2005).
41. Liu HM, Loo YM, Horner SM, Zornetzer GA, Katze MG, Gale Jr. M. The Mitochondrial targeting chaperone 14-13-3epsilon regulates a RIG-I translocon that mediates membrane association and innate anti viral immunity. Cell Host Microbe 11(5), 528-537 (2012).
42. Baril M, Racine ME, Penin F, Lamarre D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatit is C virus NS3/4A protease. J. Virol. 83(3), 1299-1311 (2009).
43. Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 146(3), 448-461 (2011).
44. Tang ED, Wang CY. MAVS self-association mediates antiviral innate immune signaling. J. Virol. 83(8), 3420-3428 (2009).
45. Dixit E, Kagan JC. Intracellular pathogen detection by RIG-I-like receptors. Adv. Immunol. 117, 99-125 (2013).
46. Odendall C,Dixit E,Stavru F,et al Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat. Immunol. 2014).
47. Okamoto M, Oshiumi H, Azuma M, Kato N, Matsumoto M, Seya T. IPS-1 is essent ial for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection. J. Immunol. 192(6), 2770-2777 (2014).
48. Zhang YL, Guo YJ, Bin L, Sun SH. Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7. J. Hepatol. 51(1), 29-38 (2009).
49. Li K, Li NL, Wei D, Pfeffer SR, Fan M, Pfeffer LM. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 55(3), 666-675 (2012).
50. Wang N, Liang Y, Devaraj S, Wang J, Lemon SM, Li K. Toll-like receptor 3 mediates establishment of an antiv iral state against hepatitis C virus in hepatoma cells. J. Virol. 83(19), 9824-9834 (2009).
51. Takahashi K, Asabe S, Wieland S et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc. Natl Acad. Sci. USA 107(16), 7431-7436 (2010).
52. Dreux M, Garaigorta U, Boyd B et al. Short-range exosomal transfer of viral RNA f rom infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 12(4), 558-570 (2012).
53. Horner SM, Gale M, Jr. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J. Interferon Cytokine Res. 29(9), 489-498 (2009).
54. Negash AA, Ramos HJ, Crochet N et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 9(4), e1003330 (2013).
55. Chattergoon MA, Latanich R, Quinn J et al. HIV and HCV activate the infl ammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog. 10(5), e1004082 (2014).
56. Shrivastava S, Mukherjee A, Ray R, Ray RB. Hepatitis C virus induces interleukin-1beta (IL-1beta)/IL-18 in circulatory and resident liver macrophages. J. Virol. 87(22), 12284-12290 (2013).
57. Arnaud N, Dabo S, Akazawa D et al. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog. 7(10), e1002289 (2011).
58. Garaigorta U, Chisari FV. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 6(6), 513-522 (2009).
59. Shimoike T, Mckenna SA, Lindhout DA, Puglisi JD. Translational insensitivity to potent activation of PKR by HCV IRES RNA. Antiviral Res. 83(3), 228-237 (2009).
60. Onomoto K, Jogi M, Yoo JS et al. Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity. PLoS ONE 7(8), e43031 (2012).
61. Pager CT, Schutz S, Abraham TM, Luo G, Sarnow P. Modulation of hepatitis C virus RNA abundance and virus release by dispersion of processing bodies and enrich ment of stress granules. Virology 435(2), 472-484 (2013).
62. Ruggieri A, Dazert E, Metz P et al. Dynamic oscillation of translation and stress granule formation mark the cellular response to virus infection. Cell Host Microbe 12(1), 71-85 (2012).
63. Ariumi Y, Kuroki M, Kushima Y et al. Hepatitis C virus hijacks P-body and stress granule components around lipid droplets. J. Virol. 85(14), 6882-6892 (2011).
64. Garaigorta U, Heim MH, Boyd B, Wieland S, Chisari FV. Hepatitis C virus (HCV) induces formation of stress granules whose proteins regulate HCV RNA replication and virus assembly and egress. J. Virol. 86(20) , 11043-11056 (2012).
65. Ding Q, Cao X, Lu J et al. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J. Hepatol. 59(1), 52-58 (2013).
66. Brass V, Berke JM, Montserret R, Blum HE, Penin F, Moradpour D. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc. Natl Acad. Sci. USA 105(38), 14545-14550 (2008).
67. Morikawa K,Lange CM,Gouttenoire J,et al Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus J. Viral Hepat. 18(5 305-315 2011).
68. Wolk B, Sansonno D, Krausslich HG et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J. Virol. 74(5), 2293-2304 (2000).
69. Kang X, Chen X, He Y et al. DDB1 is a cellular substrate of NS3/4A protease and required for hepatitis C virus replication. Virology 435(2), 385-394 (2013).
70. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl Acad. Sci. USA 102(49), 17717-17722 (2005).
71. Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062), 1167-1172 (2005).
72. Loo YM, Owen DM, Li K et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc. Natl Aca d. Sci. USA 103(15), 6001-6006 (2006).
73. Bellecave P, Sarasin-Filipowicz M, Donze O et al. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 51(4), 1127-1136 (2010).
74. Schoggins JW, Rice CM. Innate immune responses to hepatitis C virus. Curr. Top. Microbiol. Immunol. 369, 219-242 (2013).
75. Rajsbaum R, Albrecht RA, Wang MK et al. Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog. 8(11), e1003059 (2012).
76. Li K, Foy E, Ferreon JC et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad. Sci. USA 102(8), 2992-2997 (2005).
77. Zhang Z, Kim T, Bao M et al. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 34(6), 866-878 (2011).
78. Yang Y, Liang Y, Qu L et al. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc. Natl Acad. Sci. USA 104(17), 7253-7258 (2007).
79. Qu L, Feng Z, Yamane D et al. Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD. PLoS Pathog. 7(9), 1002169 (2011).
80. Romero-Brey I, Merz A, Chiramel A et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog. 8(12), e1003056 (2012).
81. Kim SJ, Syed GH, Khan M et al. Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. Proc. Natl Acad. Sci. USA 111(17), 6413-6418 (2014).
82. Castanier C, Garcin D, Vazquez A, Arnoult D. Mitochondrial dynamics regulate the RIG-I-like receptor antiviral pathway. EMBO Rep. 11(2), 133-138 (2010).
83. Pagliaccetti NE, Robek MD. Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus. J. Interferon Cytokine Res. 30(8), 585-590 (2010).
84. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 60(9), 1284-1293 (2011).
85. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4(3), e1000017 (2008).
86. Park H, Serti E, Eke O et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 56(6), 2060-2070 (2012).
87. Thomas E, Gonzalez VD, Li Q et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142(4), 978-988 (2012).
88. Marukian S,Andrus L,Sheahan TP,et al Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures Hepatology 54 6 1913-1923 2011).
89. Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons alpha and lambda inhibit hepatitis C virus replication with di stinct signal transduction and gene regulation kinetics. Gastroenterology 131(6), 1887-1898 (2006).
90. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with ch ronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4), 1338-1345, 1345, e1331-1337 (2010).
91. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009).
92. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009) .
93. Dill MT, Duong FH, Vogt JE et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140(3), 1021-1031 (2011).
94. Langhans B, Kupfer B, Braunschweiger I et al. Interferon-lambda serum levels in hepatitis C. J. Hepatol. 54(5), 859-865 (2011).
95. Yoshio S, Kanto T, Kuroda S et al. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-lambda in response to hepatitis C virus. Hepatology 57(5), 1705-1715 (2013).
96. Fukuhara T, Taketomi A, Motomura T et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139(5), 1577-1585 (2010).
97. Sheahan T, Imanaka N, Marukian S et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15(2), 190-202 (2014).
98. Mcfarland AP, Horner SM, Jarret A et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat. Immunol. 15(1), 72-79 (2014).
99. Prokunina-Olsson L, Muchmore B, Tang W et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45(2), 164-171 (2013).
100. De Castellarnau M, Aparicio E, Parera M et al. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-alpha and ribavir in therapy in HCV/HIV-1 coinfected patients. PLoS ONE 7(2), e31016 (2012).
101. Bibert S, Roger T, Calandra T et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J. Exp. Med. 210(6), 1109-1116 (2013).
102. O'brien TR, Prokunina-Olsson L, Donnelly RP. IFN-lambda4: the paradoxical new member of the interferon lambda family. J. Interferon Cytokine Res. (2014).
103. Stone AE, Giugliano S, Schnell G et al. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog. 9(4), e1003316 (2013).
104. Metz P, Reuter A, Bender S, Bartenschlager R. Interferon-stimulated genes and their role in controlling hepatitis C virus. J. Hepatol.59(6), 1331-1341 (2013).
105. Metz P, Dazert E, Ruggieri A et al. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 56(6), 2082-2093 (2012).
106. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA 105(19), 7034-7039 (2008).
107. Wieland S, Makowska Z, Campana B et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59(6), 2121-2130 (2014).
108. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J. Virol. 79(15), 9369-9380 (2005).
109. Lanford RE, Feng Z, Chavez D et al. Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc. Natl Acad. Sci. USA 108(27), 11223-11228 (2011).
110. Chen L,Borozan I,Sun J,et al Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection Gastroenterology 138 3), 1123-1133 e1121-1123 2010).
111. Honda M, Sakai A, Yamashita T et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139(2), 499-509 (2010).
112. Sarasin-Filipowicz M, Wang X, Yan M et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol. Cell. Biol. 29(17), 4841-4851 (2009).
113. Liang Y, Shilagard T, Xiao SY et al. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 137(4), 1448-1458 (2009).
114. Kandathil AJ, Graw F, Quinn J et al. Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology 145(6), 1404-1413 (2013).
115. Lau DT, Negash A, Chen J et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroentero logy 144(2), 402-413 e412 (2013).
116. Fusco DN, Brisac C, John SP et al. A genetic screen identifies interferon-alpha effector genes required to suppress hepatitis C virus replication. Gastroenterology 144(7), 1438-1449, 1449 e1431-1439 (2013).
117. Zhao H, Lin W, Kumthip K et al. A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. J. Hepatol. 56(2), 326-333 (2012).
118. Malathi K, Saito T, Crochet N, Barton DJ, Gale Jr. M., Silverman RH. RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. RNA 16(11), 2108-2119 (2010).
119. Han JQ, Barton DJ. Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 8(4), 512-525 (2002).
120. Taguchi T, Nagano-Fujii M, Akutsu M et al. Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J. Gen. Virol. 85(P t 4), 959-969 (2004).
121. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J. Virol. 85(24), 12881-12889 (2011).
122. Wilkins C, Woodward J, Lau DT et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 57(2), 461-469 (2013).
123. Yao L, Dong H, Zhu H et al. Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line. J. Viral Hepat. 18(10), e523-529 (2011).
124. Amini-Bavil-Olyaee S, Choi YJ, Lee JH et al. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 13(4), 452-464 (2013).
125. Gao L, Aizaki H, He JW, Lai MM. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J. Virol. 78(7), 3480-348 8 (2004).
126. Wang H, Perry JW, Lauring AS, Neddermann P, De Francesco R, Tai AW. Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and c holesterol trafficking. Gastroenterology 146(5), 1373-1385, e1371-1311 (2014).
127. Helbig KJ, Eyre NS, Yip E et al. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. Hepatology 54(5), 1506-1517 (2011).
128. Wang S, Wu X, Pan T et al. Viperin inhibits hepatitis C virus replication by interfering with binding of NS5A to host protein hVAP-33. J. Gen. Virol. 93(Pt 1), 83-92 (2012).
129. Arnaud N, Dabo S, Maillard P et al. Hepatitis C virus controls interferon production through PKR activation. PLoS ONE 5(5), e10575 (2010).
130. Kang W, Sung PS, Park SH et al. Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector function s. Gastroenterology 146(5), 1351-1360, e1351-1354 (2014).
131. Taylor DR,Shi ST,Romano PR,Barber GN,Lai MM Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein Science 285 5424 107-110 1999).
132. Gale MJ, Jr., Korth MJ, Tang NM et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein k inase by the nonstructural 5A protein. Virology 230(2), 217-227 (1997).
133. Heim MH. Innate immunity and HCV. J. Hepatol. 58(3), 564-574 (2013).
134. Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J. Virol. 79(10), 6291-6298 (200 5).
135. Dafa-Berger A, Kuzmina A, Fassler M, Yitzhak-Asraf H, Shemer-Avni Y, Taube R. Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin. Virology 428(2), 98-111 (2012).
136. Itsui Y, Sakamoto N, Kurosaki M et al. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J. Viral Hepat. 13( 10), 690-700 (2006).
137. Pichlmair A, Lassnig C, Eberle CA et al. IFIT1 is an antiviral protein that recognizes 5-triphosphate RNA. Nat. Immunol. 12(7), 624-630 (2011).
138. Liu XY, Chen W, Wei B, Shan YF, Wang C. IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J. Immunol. 187(5), 2559-2568 (2011).
139. Kanazawa N, Kurosaki M, Sakamoto N et al. Regulation of hepatitis C virus replication by interferon regulatory factor 1. J. Virol. 78(18), 9713-9720 (2004).
140. Jiang D, Guo H, Xu C et al. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J. Virol. 82(4), 1665-1678 (2008).
141. Kwon YC, Kang JI, Hwang SB, Ahn BY. The ribonuclease L-dependent antiviral roles of human 2,5-oligoadenylate synthetase family members against hepatitis C virus. FEBS Lett. 587(2), 156-164 (2013).